Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund.

Genmab is listed on the Copenhagen Stock Exchange in Denmark,[8] with American depositary receipts traded on the NASDAQ in the US.

[9] Genmab's technology is licensed from Medarex to create fully human high affinity antibodies using transgenic mice.

[12] In 2005, the Biotechnology Industry Organization (BIO) and the Long Island Life Sciences Initiative honored Genmab with a James D. Watson Helix Award.

[13] 2008 saw the company purchasing a 22,000-litre, 36-acre antibody manufacturing plant in Brooklyn Park, Minnesota from PDL BioPharma, with plans to retain all 170 employees thereat.

[5] In 2008, the world was experiencing a financial crisis as a whole, and GlaxoSmithKline decided to exit oncology, which impacted co-development of ofatumumab, an oncology-directed product.

Drakeman was one of Genmab's co-founders and was appointed chief executive officer (CEO) of the company upon incorporation in 1999, also joining the board of directors.

[5] Since the company started in 1999, he had been Genmab's chief scientific officer (CSO); he had concurrently served as head of research, then president of R&D.

In October 2001, this was replaced by a direct license agreement where Amgen retained exclusive commercialization options for the products through phase II.

Amgen has discontinued development of the IL15 antibody, AMG 714, in psoriasis and rheumatoid arthritis based on disappointing results from recent clinical studies.

[19] The company has 8 approved antibodies (monoclonal and bispecific) used in 8 marketed products, covering cancer indications and autoimmune diseases.